Workflow
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
Globenewswireยท2025-08-12 08:00

Core Viewpoint - The collaboration between Rakovina Therapeutics and NanoPalm Ltd. aims to develop novel small-molecule oncology therapeutics, starting with the dual PARP-HDAC inhibitor kt-3283, utilizing NanoPalm's advanced pLNP delivery technology [1][2][3]. Group 1: Collaboration Details - A non-binding Letter of Intent (LOI) has been signed to form a joint venture for co-developing oncology therapeutics [1]. - The joint venture will focus on advancing kt-3283 through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][15]. - The collaboration combines Rakovina's AI-enabled drug discovery engine with NanoPalm's self-targeting pLNP delivery system, enhancing therapeutic delivery precision and efficacy [2][4]. Group 2: Technology and Innovation - kt-3283 is a potent small-molecule inhibitor that targets PARP and HDAC, showing enhanced cytotoxicity in preclinical studies, particularly in Ewing sarcoma, breast, and ovarian cancer models [3]. - NanoPalm's pLNP technology, originally developed for gene therapy, improves tissue specificity and systemic tolerability, representing a strategic entry into oncology [4][5]. - The collaboration aims to leverage AI-assisted design to enhance the delivery profile of small-molecule therapies, creating a robust pipeline for future commercialization [6][8]. Group 3: Operational and Strategic Aspects - The joint venture will be based in Saudi Arabia, aligning with the Kingdom's National Biotechnology Strategy and aiming for global development and commercialization [8][11]. - Intellectual property arising from the collaboration will be jointly owned, with each party retaining rights to their respective background IP [9]. - The partners will co-fund the joint venture and pursue third-party investments, sharing ownership, risk, and potential upside equally [15].